CD8A and neoplasm: Studies in mouse models demonstrate that SMC therapy indirectly rejuvenates exhausted CD8+ T cells by targeting tumor-associated macrophages (TAM) for M1-like polarization, while OV therapy promotes CD8+ T-cell recruitment and serves as a non-specific immune system adjuvant.